<p>HC Wainwright 的研究分析师发布了关于 Belite Bio（纳斯达克股票代码：BLTE）2025 年第一季度每股收益（EPS）的预估报告，预计公司将在本季度实现每股收益为（$0.29）。HC Wainwright 分析师 Y. Chen 预计，该公司全年每股收益的共识估值为（$1.08）。HC Wainwright 还预测了 Belite Bio 2025 年第二季度每股收益为（$0.29），第三季度每股收益为（$0.29），第四季度每股收益为（$0.29）。目前，HC Wainwright 给予该股票 “买入” 评级，并设定目标股价为$60.00。</p>
<p>其他几家分析师最近也发布了关于该公司的报告。Benchmark 在一份研究报告中重申了对 Belite Bio 的 “买入” 评级，并设定了$57.00 的目标股价。Cantor Fitzgerald 在 6 月 20 日星期四的一份研究报告中重申了对 Belite Bio 的 “超重” 评级。</p>
<p><strong>获取我们关于 Belite Bio 的最新研究报告</strong></p>
<h2>Belite Bio 股价上涨 3.3%</h2>
<p>BLTE 股票周三开盘价为$50.16。该公司的市值为 14.9 亿美元，市盈率为-42.51，贝塔系数为-1.47。Belite Bio 过去一年的最低股价为$20.32，最高股价为$50.66。该公司的 50 天简单移动平均线为$48.43，200 天简单移动平均线为$44.90。</p>
<p>Belite Bio（纳斯达克股票代码：BLTE）上次公布季度财报是在 5 月 13 日星期一。该公司本季度每股收益为（$0.27），超过了（$0.34）的共识估值。</p>
<h2>对 Belite Bio 的对冲基金看法</h2>
<p>一家机构投资者最近在 Belite Bio 股票中建立了新头寸。根据最近向美国证券交易委员会（SEC）披露的信息，Armistice Capital LLC 在去年第四季度收购了 Belite Bio，Inc（纳斯达克股票代码：BLTE）的新股份。该公司收购了该公司的 36,000 股股票，价值约 164.7 万美元。截至最近一次向 SEC 提交的文件，Armistice Capital LLC 拥有 Belite Bio 约 0.13% 的股份。目前，0.53% 的股份由机构投资者和对冲基金持有。</p>
<h2>Belite Bio 公司简介（获取免费报告）</h2>
<p>Belite Bio，Inc 是一家临床阶段的生物制药药物开发公司，致力于研究和开发针对美国未满足医疗需求的视网膜退行性眼疾的新型治疗药物。该公司的主导产品候选药物是 LBS-008（Tinlarebant），一种口服一日一次的片剂，用于维持常染色体隐性 Stargardt 病和地理性萎缩患者视网膜组织的健康和完整性。</p>
<h2>参见</h2>
<ul>
<li>我们喜欢的五支股票胜过 Belite Bio</li>
<li>爆发股票：是什么以及如何识别</li>
<li>NVIDIA 股票在财报公布前是否值得购买？</li>
<li>股票板块对成功投资有何重要性？</li>
<li>Instacart 股票凭借利润和人工智能推动购物车发展势头</li>
<li>股票拆分意味着什么？</li>
<li>PROCEPT BioRobotics 是否是外科机器人领域的下一个大事件？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxURQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxURQ"/></p>
<p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和来自 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 在亿万富翁买光之前，先抢购这支 “人工智能燃料” 股票（来自市场后方）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4"/></p>
<h2>现在是否值得投资$1,000 在 Belite Bio？</h2>
<p>在考虑 Belite Bio 之前，您可能想听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五支顶尖分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 Belite Bio 不在名单上。</p>
<p>尽管 Belite Bio 目前在分析师中有 “买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
<p>查看这五支股票</p>

BLTE

<p>Belite Bio, Inc（纳斯达克股票代码：BLTE）收到了 HC Wainwright 对 2025 年第一季度盈利的预估，预计每股收益为{{.Question}}.29 美元，维持 “买入” 评级和目标股价为.00 美元。当前全年盈利的共识为（.08）美元每股。其他分析师，包括 Benchmark 和 Cantor Fitzgerald，重申了买入和超配评级。该股最近交易价为.16 美元，市值为.49 十亿美元。Armistice Capital 最近收购了该公司的新股份，持有机构投资者持有的 0.53% 股份。Belite 专注于开发治疗视网膜疾病的药物</p>

<p>Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Belite Bio in a report issued on Tuesday, August 13th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.29) per share for the quarter. HC Wainwright currently has a &#34;Buy&#34; rating and a $60.00 price target on the stock. The consensus estimate for Belite Bio's current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Belite Bio's Q2 2025 earnings at ($0.29) EPS, Q3 2025 earnings at ($0.29) EPS and Q4 2025 earnings at ($0.29) EPS.</p>
<div class="lb-trans"><p>HC Wainwright 的研究分析师发布了关于 Belite Bio（纳斯达克股票代码：BLTE）2025 年第一季度每股收益（EPS）的预估报告，预计公司将在本季度实现每股收益为（$0.29）。HC Wainwright 分析师 Y. Chen 预计，该公司全年每股收益的共识估值为（$1.08）。HC Wainwright 还预测了 Belite Bio 2025 年第二季度每股收益为（$0.29），第三季度每股收益为（$0.29），第四季度每股收益为（$0.29）。目前，HC Wainwright 给予该股票 “买入” 评级，并设定目标股价为$60.00。</p>
</div><p>Several other analysts also recently issued reports on the company. Benchmark reiterated a &#34;buy&#34; rating and set a $57.00 price target on shares of Belite Bio in a research note on Tuesday. Cantor Fitzgerald reiterated an &#34;overweight&#34; rating on shares of Belite Bio in a research note on Thursday, June 20th.</p>
<div class="lb-trans"><p>其他几家分析师最近也发布了关于该公司的报告。Benchmark 在一份研究报告中重申了对 Belite Bio 的 “买入” 评级，并设定了$57.00 的目标股价。Cantor Fitzgerald 在 6 月 20 日星期四的一份研究报告中重申了对 Belite Bio 的 “超重” 评级。</p>
</div><p><strong>Get Our Latest Research Report on Belite Bio</strong></p>
<div class="lb-trans"><p><strong>获取我们关于 Belite Bio 的最新研究报告</strong></p>
</div><h2>Belite Bio Trading Up 3.3 %</h2>
<div class="lb-trans"><h2>Belite Bio 股价上涨 3.3%</h2>
</div><p>BLTE stock opened at $50.16 on Wednesday. The firm has a market cap of $1.49 billion, a PE ratio of -42.51 and a beta of -1.47. Belite Bio has a 1 year low of $20.32 and a 1 year high of $50.66. The company has a fifty day simple moving average of $48.43 and a 200 day simple moving average of $44.90.</p>
<div class="lb-trans"><p>BLTE 股票周三开盘价为$50.16。该公司的市值为 14.9 亿美元，市盈率为-42.51，贝塔系数为-1.47。Belite Bio 过去一年的最低股价为$20.32，最高股价为$50.66。该公司的 50 天简单移动平均线为$48.43，200 天简单移动平均线为$44.90。</p>
</div><p>Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its quarterly earnings results on Monday, May 13th. The company reported ($0.27) EPS for the quarter, topping the consensus estimate of ($0.34) by $0.07.</p>
<div class="lb-trans"><p>Belite Bio（纳斯达克股票代码：BLTE）上次公布季度财报是在 5 月 13 日星期一。该公司本季度每股收益为（$0.27），超过了（$0.34）的共识估值。</p>
</div><h2>Hedge Funds Weigh In On Belite Bio</h2>
<div class="lb-trans"><h2>对 Belite Bio 的对冲基金看法</h2>
</div><p>An institutional investor recently bought a new position in Belite Bio stock. Armistice Capital LLC acquired a new stake in Belite Bio, Inc (NASDAQ:BLTE - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 36,000 shares of the company's stock, valued at approximately $1,647,000. Armistice Capital LLC owned about 0.13% of Belite Bio as of its most recent filing with the Securities and Exchange Commission (SEC). 0.53% of the stock is currently owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一家机构投资者最近在 Belite Bio 股票中建立了新头寸。根据最近向美国证券交易委员会（SEC）披露的信息，Armistice Capital LLC 在去年第四季度收购了 Belite Bio，Inc（纳斯达克股票代码：BLTE）的新股份。该公司收购了该公司的 36,000 股股票，价值约 164.7 万美元。截至最近一次向 SEC 提交的文件，Armistice Capital LLC 拥有 Belite Bio 约 0.13% 的股份。目前，0.53% 的股份由机构投资者和对冲基金持有。</p>
</div><h2>Belite Bio Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>Belite Bio 公司简介（获取免费报告）</h2>
</div><p>Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients.</p>
<div class="lb-trans"><p>Belite Bio，Inc 是一家临床阶段的生物制药药物开发公司，致力于研究和开发针对美国未满足医疗需求的视网膜退行性眼疾的新型治疗药物。该公司的主导产品候选药物是 LBS-008（Tinlarebant），一种口服一日一次的片剂，用于维持常染色体隐性 Stargardt 病和地理性萎缩患者视网膜组织的健康和完整性。</p>
</div><h2>See Also</h2>
<ul>
<li>Five stocks we like better than Belite Bio</li>
<li>Breakout Stocks: What They Are and How to Identify Them</li>
<li>Is NVIDIA Stock a Buy Ahead of Earnings?</li>
<li>Why Are Stock Sectors Important to Successful Investing?</li>
<li>Instacart Stock Gains Momentum with Profits and AI-Powered Carts</li>
<li>What Does a Stock Split Mean?</li>
<li>Is PROCEPT BioRobotics the Next Big Thing in Surgical Robotics?</li>
</ul>
<div class="lb-trans"><h2>参见</h2>
<ul>
<li>我们喜欢的五支股票胜过 Belite Bio</li>
<li>爆发股票：是什么以及如何识别</li>
<li>NVIDIA 股票在财报公布前是否值得购买？</li>
<li>股票板块对成功投资有何重要性？</li>
<li>Instacart 股票凭借利润和人工智能推动购物车发展势头</li>
<li>股票拆分意味着什么？</li>
<li>PROCEPT BioRobotics 是否是外科机器人领域的下一个大事件？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QkxURQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=BLTE"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>这则即时新闻警报是由 MarketBeat 的叙事科技和来自 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前经过 MarketBeat 编辑团队的审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Secure this &#34;AI Fuel&#34; Stock Before the Billionaires Buy It All (From Behind the Markets)(Ad)</p>
<div class="lb-trans"><p>→ 在亿万富翁买光之前，先抢购这支 “人工智能燃料” 股票（来自市场后方）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD05MTQ4" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=9148&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in Belite Bio right now?</h2>
<div class="lb-trans"><h2>现在是否值得投资$1,000 在 Belite Bio？</h2>
</div><p>Before you consider Belite Bio, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Belite Bio 之前，您可能想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Belite Bio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶尖和表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五支顶尖分析师悄悄告诉客户在更广泛市场注意之前购买的股票...而 Belite Bio 不在名单上。</p>
</div><p>While Belite Bio currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 Belite Bio 目前在分析师中有 “买入” 评级，但顶级分析师认为这五支股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五支股票</p>
</div>

HC Wainwright 发布了 Belite Bio, Inc（纳斯达克股票代码：BLTE）2025 年第一季度的收益预测报告